Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IO Biotech, Inc. stock logo
IOBT
IO Biotech
$1.89
+11.2%
$1.34
$0.66
$1.95
$112M0.36293,090 shs433,823 shs
Kamada Ltd. stock logo
KMDA
Kamada
$7.56
$7.21
$5.08
$9.16
$434.74M0.9695,669 shs44,002 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$8.50
+3.2%
$8.91
$5.04
$15.36
$413.32M1.06921,766 shs537,496 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$5.27
+4.4%
$3.73
$1.87
$11.40
$441.05M-0.111.45 million shs830,336 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IO Biotech, Inc. stock logo
IOBT
IO Biotech
+11.18%+31.25%+43.18%+119.74%+42.11%
Kamada Ltd. stock logo
KMDA
Kamada
0.00%-3.69%+5.73%+16.31%+29.90%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
+3.16%-7.31%-7.21%+43.10%-37.32%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
+4.36%+7.77%+31.42%+119.13%-45.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3.6491 of 5 stars
3.75.00.00.02.82.50.6
Kamada Ltd. stock logo
KMDA
Kamada
4.3137 of 5 stars
3.33.00.00.02.71.74.4
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
4.0223 of 5 stars
3.41.00.04.61.53.30.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.7536 of 5 stars
3.31.00.04.12.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3.33
Buy$9.33393.83% Upside
Kamada Ltd. stock logo
KMDA
Kamada
2.67
Moderate Buy$13.0071.96% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$31.63272.06% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63196.49% Upside

Current Analyst Ratings Breakdown

Latest IOBT, KMDA, TERN, and RGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/14/2025
IO Biotech, Inc. stock logo
IOBT
IO Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
4/17/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/AN/AN/AN/A$0.71 per shareN/A
Kamada Ltd. stock logo
KMDA
Kamada
$160.95M2.70$0.49 per share15.38$4.51 per share1.68
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$83.33M5.12N/AN/A$5.24 per share1.62
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IO Biotech, Inc. stock logo
IOBT
IO Biotech
-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)
Kamada Ltd. stock logo
KMDA
Kamada
$14.46M$0.2926.0723.630.929.60%6.31%4.43%8/13/2025 (Estimated)
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)

Latest IOBT, KMDA, TERN, and RGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.09N/AN/AN/A$158.59 millionN/A
8/12/2025Q2 2025
IO Biotech, Inc. stock logo
IOBT
IO Biotech
-$0.35N/AN/AN/AN/AN/A
8/7/2025Q2 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$1.13N/AN/AN/AN/AN/A
8/4/2025Q2 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/12/2025Q1 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.41$0.12-$0.29$0.12$105.35 million$89.01 million
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/A
2.32
2.32
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.30
1.93
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
2.93
2.93
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
30.89
30.89

Institutional Ownership

CompanyInstitutional Ownership
IO Biotech, Inc. stock logo
IOBT
IO Biotech
54.76%
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
IO Biotech, Inc. stock logo
IOBT
IO Biotech
4.80%
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3065.88 million62.72 millionNot Optionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.51 million36.75 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.16 million43.75 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million86.03 millionNot Optionable

Recent News About These Companies

3 Penny Stocks Wall Street Sees With 243% Upside

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
IO Biotech stock logo

IO Biotech NASDAQ:IOBT

$1.89 +0.19 (+11.18%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$1.90 +0.01 (+0.53%)
As of 07:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Kamada stock logo

Kamada NASDAQ:KMDA

$7.56 0.00 (0.00%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$7.73 +0.17 (+2.24%)
As of 06:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$8.50 +0.26 (+3.16%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$8.47 -0.03 (-0.35%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$5.27 +0.22 (+4.36%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$5.31 +0.04 (+0.83%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.